Overview
Updated 14 Jul 2026
David J. Schneider, MD, is Professor of Medicine at University of Vermont, Larner College of Medicine / UVM Medical Center (UVM Health Network). The public record shows 263 publications with 13,881 citations (h-index 53), centered on Coronary Artery Disease / ACS. It also documents an investigator role on 6 registered clinical trials, industry payments reported by 2 companies, 4 NIH-funded awards (2000–2025).
- Most recent indexed publication: 2025 · Circulation. Cardiovascular interventions
- Top research focus: Coronary Artery Disease / ACS
- 6 registered trials on ClinicalTrials.gov
- Open Payments reporting from 2 companies
Generated from the cited public record · current as of 14 Jul 2026. Every fact links its source below.
Indications focusfrom trials led + research topics
Research focusOpenAlex concept fingerprint
Drugs & moleculesacross trials, industry payments and publications
Works withtrial sponsors and companies reporting payments
Scholarshipindexed output and impact (OpenAlex)
View publications ↓Distinct works indexed by OpenAlex, matched via ORCID; 3 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industrytrials, payments and federal funding
Public positionssourced statements on record
- "Care, Research and Education: Why Vermont Needs Academic Medicine"
op-ed opposing recommendations (from an Oliver Wyman consulting report) to cut clinician time spent on teaching and research …
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uvmlarnermedblog.com ↗
Clinical trials
Updated 14 Jul 2026
Listed as an investigator on 6 registered studies on ClinicalTrials.gov. The most recent:
- Assessment of Individual Risk of Cardiovascular Events by Platelet FcGammaRIIa
Sponsor: Prolocor, Inc
InvestigatorCompletedNCT05175261 - Cangrelor to Clopidogrel or Prasugrel Transition Study
Sponsor: The Medicines Company
InvestigatorPhase 2CompletedNCT01979445 - Cangrelor Prasugrel Transition Study
Sponsor: The Medicines Company
InvestigatorPhase 2CompletedNCT01852019
Industry payments
Updated 14 Jul 2026
2 companies reported payments to CMS in program years 2023–2025. These are public disclosures, not judgments. The latest:
- Janssen Research & Development, LLCProgram year20251 payment
- Chiesi USA, Inc.Program year20232 payments
NIH funding
Updated 14 Jul 2026
4 NIH research awards on record, funded 2000–2025 per NIH RePORTER. The latest:
- Computational Analyses of Family Auditory Communication: Linking Behavior, Vocalization, and Neural Dynamics
New York University
FY2026$854,818U01DA063581 - Platelet Expression of FcgammaRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial Atherosclerosis
University of Southern California
FY2026$759,519R01NS123734
Publications
Updated 14 Jul 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Predictive Value of Platelet FcγRIIa in Patients Treated With PCI Compared With Medical Therapy Alone After Myocardial Infarction.
Circulation. Cardiovascular interventions
2025 - Platelet FcγRIIa Expression in Ischemic Stroke: A Marker of Increased Platelet Reactivity.
Stroke (Hoboken, N.J.)
2022
Contact
An office address from a public listing. This research profile has no federal registry record to draw from.
Office address
Colchester Research Facility, 360 S Park Drive, Colchester, VT 05446
Background & recognition
Updated 14 Jul 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Educationdegrees and training on record
- Internal Medicine Residency and Chief Medical Residency
University of Colorado Health Sciences Center
- Fellowship in Cardiovascular Disease
Washington University, St. Louis
Editorial & leadership rolesjournal and society appointments
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vermontbiz.com ↗
- Chief of Cardiology
UVM Medical Center
Awards & honorshonors on the public record
Secondary affiliationsappointments beyond the home institution
- Division of Cardiovascular Medicine
Department of Medicine, University of Vermont
Media & interviewspress, podcasts and appearances
- "David Schneider, MD, Medical Director, Cardiovascular Services"
profile video, The UVM Medical Center (YouTube)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗ - "R1 Larner Spotlight: Cardiologist David Schneider, M.D., and a New Biomarker Test"
feature on Schneider's FcγRIIa/Prolocor pFCG platelet biomarker research
- "Biomarker test developed by UVMMC cardiologist offers insight to prevent recurrent heart attacks"
Vermont Business Magazine feature on Schneider's research
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vermontbiz.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Online presence
Updated 14 Jul 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Mentions by otherswhere others cite or feature them
- YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this specialty yet.